中华核医学与分子影像杂志
中華覈醫學與分子影像雜誌
중화핵의학여분자영상잡지
Chinese Journal of Nuclear Medicine and Molecular Imaging
2013年
1期
42-45
,共4页
格雷夫斯病%放射疗法%碘放射性同位素%淋巴细胞%肿瘤坏死因子%受体,肿瘤坏死因子
格雷伕斯病%放射療法%碘放射性同位素%淋巴細胞%腫瘤壞死因子%受體,腫瘤壞死因子
격뢰부사병%방사요법%전방사성동위소%림파세포%종류배사인자%수체,종류배사인자
Graves' disease%Radiotherapy%Iodine radioisotopes%Lymphocytes%Tumor necrosis factor%Receptors,tumor necrosis factor
目的 探讨Graves病患者131I治疗前后外周血淋巴细胞亚群OX40和OX40L表达的变化及其临床意义.方法 应用免疫荧光和流式细胞术分析32例Graves病患者131I治疗前后和25例健康志愿者的外周血T细胞亚群和B细胞的百分率,检测OX40和OX40L在受检者CD4+ T细胞和CD19+B细胞上表达的变化.对OX40、OX40L与FT3、FT4和TRAb的关系作直线相关分析.2组间计量数据比较采用两样本t检验.结果 Graves病患者外周血CD4+ T细胞百分率为(34.36±6.73)％、CD4/CD8比值为1.24±0.26,与健康对照组相比[(45.60±5.72)％、1.84 ±0.37]明显减少(t =2.634和2.125,均P＜0.05),而CD19+B细胞数量为(21.42±3.92)％,较健康对照组的(15.35±3.15)％明显增加(t=2.653,P＜0.05).Graves病患者CD4 T细胞表面OX40的表达水平为(12.92±2.26)％,较健康对照组的(4.19±1.45)％明显上调(t=2.112,P＜0.05)；CD19B细胞表面OX40L为(15.33±3.75)％,较健康对照组的(8.64±1.73)％表达水平高(t=2.467,P＜0.05).Graves病患者经131I治疗后CD4+ T细胞表面OX40的表达水平为(7.65±1.64)％,CD19B细胞表面OX40L为(11.50±2.72)％,均较治疗前明显改善(t=2.795和2.393,均P＜0.05).Graves病患者131I治疗后FT3、FT4和TRAb较治疗前明显下降(4.53±2.54和20.79±6.05、13.69±4.35和49.65±10.12、11.74 ±6.19和24.78±8.46;t =2.219、2.441和2.293,均P＜0.05).FT3、FT4与CD4+ T细胞上OX40的表达呈正相关(r=0.65和0.73,均P＜0.05).TRAb与CD19+ OX40L+B细胞呈正相关(r=0.76,P＜0.05).结论 OX40和OX40L在Graves病患者淋巴细胞的活化和抗体产生过程中发挥了重要作用,与疾病的发生、发展密切相关.131I治疗不仅通过β射线破坏甲状腺滤泡,同时影响机体T、B细胞免疫功能,促进Graves病好转.
目的 探討Graves病患者131I治療前後外週血淋巴細胞亞群OX40和OX40L錶達的變化及其臨床意義.方法 應用免疫熒光和流式細胞術分析32例Graves病患者131I治療前後和25例健康誌願者的外週血T細胞亞群和B細胞的百分率,檢測OX40和OX40L在受檢者CD4+ T細胞和CD19+B細胞上錶達的變化.對OX40、OX40L與FT3、FT4和TRAb的關繫作直線相關分析.2組間計量數據比較採用兩樣本t檢驗.結果 Graves病患者外週血CD4+ T細胞百分率為(34.36±6.73)％、CD4/CD8比值為1.24±0.26,與健康對照組相比[(45.60±5.72)％、1.84 ±0.37]明顯減少(t =2.634和2.125,均P＜0.05),而CD19+B細胞數量為(21.42±3.92)％,較健康對照組的(15.35±3.15)％明顯增加(t=2.653,P＜0.05).Graves病患者CD4 T細胞錶麵OX40的錶達水平為(12.92±2.26)％,較健康對照組的(4.19±1.45)％明顯上調(t=2.112,P＜0.05)；CD19B細胞錶麵OX40L為(15.33±3.75)％,較健康對照組的(8.64±1.73)％錶達水平高(t=2.467,P＜0.05).Graves病患者經131I治療後CD4+ T細胞錶麵OX40的錶達水平為(7.65±1.64)％,CD19B細胞錶麵OX40L為(11.50±2.72)％,均較治療前明顯改善(t=2.795和2.393,均P＜0.05).Graves病患者131I治療後FT3、FT4和TRAb較治療前明顯下降(4.53±2.54和20.79±6.05、13.69±4.35和49.65±10.12、11.74 ±6.19和24.78±8.46;t =2.219、2.441和2.293,均P＜0.05).FT3、FT4與CD4+ T細胞上OX40的錶達呈正相關(r=0.65和0.73,均P＜0.05).TRAb與CD19+ OX40L+B細胞呈正相關(r=0.76,P＜0.05).結論 OX40和OX40L在Graves病患者淋巴細胞的活化和抗體產生過程中髮揮瞭重要作用,與疾病的髮生、髮展密切相關.131I治療不僅通過β射線破壞甲狀腺濾泡,同時影響機體T、B細胞免疫功能,促進Graves病好轉.
목적 탐토Graves병환자131I치료전후외주혈림파세포아군OX40화OX40L표체적변화급기림상의의.방법 응용면역형광화류식세포술분석32례Graves병환자131I치료전후화25례건강지원자적외주혈T세포아군화B세포적백분솔,검측OX40화OX40L재수검자CD4+ T세포화CD19+B세포상표체적변화.대OX40、OX40L여FT3、FT4화TRAb적관계작직선상관분석.2조간계량수거비교채용량양본t검험.결과 Graves병환자외주혈CD4+ T세포백분솔위(34.36±6.73)％、CD4/CD8비치위1.24±0.26,여건강대조조상비[(45.60±5.72)％、1.84 ±0.37]명현감소(t =2.634화2.125,균P＜0.05),이CD19+B세포수량위(21.42±3.92)％,교건강대조조적(15.35±3.15)％명현증가(t=2.653,P＜0.05).Graves병환자CD4 T세포표면OX40적표체수평위(12.92±2.26)％,교건강대조조적(4.19±1.45)％명현상조(t=2.112,P＜0.05)；CD19B세포표면OX40L위(15.33±3.75)％,교건강대조조적(8.64±1.73)％표체수평고(t=2.467,P＜0.05).Graves병환자경131I치료후CD4+ T세포표면OX40적표체수평위(7.65±1.64)％,CD19B세포표면OX40L위(11.50±2.72)％,균교치료전명현개선(t=2.795화2.393,균P＜0.05).Graves병환자131I치료후FT3、FT4화TRAb교치료전명현하강(4.53±2.54화20.79±6.05、13.69±4.35화49.65±10.12、11.74 ±6.19화24.78±8.46;t =2.219、2.441화2.293,균P＜0.05).FT3、FT4여CD4+ T세포상OX40적표체정정상관(r=0.65화0.73,균P＜0.05).TRAb여CD19+ OX40L+B세포정정상관(r=0.76,P＜0.05).결론 OX40화OX40L재Graves병환자림파세포적활화화항체산생과정중발휘료중요작용,여질병적발생、발전밀절상관.131I치료불부통과β사선파배갑상선려포,동시영향궤체T、B세포면역공능,촉진Graves병호전.
Objective To investigate the clinical value and the expression of OX40/OX40L from lymphocytes of patients with Graves' disease (GD) before and after 131I therapy.Methods The expression of OX40/OX40L on T,B lymphocytes and the percentage of lymphocyte subsets were analyzed using immunofluorescence staining and flow cytometry in 32 patients with GD before and after 131I therapy.Twenty-five healthy subjects were considered as the control group.The data between GD patients and controls were compared with two-sample t test.The correlation between the expression of OX40/OX40L and the function of thyroid (FT3,FT4 and TRAb level) was performed with linear correlation analysis.Results Compared with the healthy subjects,the percentage of CD4+ T cells and ratio of CD4+/CD8+ were decreased ((34.36 ±6.73)％ vs (45.60-±5.72)％,t=2.634; 1.24±0.26 vs 1.84±0.37,t=2.125,both P＜0.05).Whereas the percentage of CD19+ B cells in patients with GD were significantly higher than that in healthy subjects ((21.42 ±3.92)％ vs (15.35 ± 3.15)％,t =2.653,P ＜0.05).The expression of OX40 increased in CD4+ T lymphocytes ((12.92 ± 2.26) ％) and OX40L expression was up-regulated in CD19+ B lymphocytes ((15.33 ± 3.75)％) of patients with GD,compared with the healthy subjects ((4.19 ±1.45) ％ and (8.64 ± 1.73) ％,respectively,t =2.112 and 2.467,both P ＜ 0.05).The expression of OX40 in CD4+ T lymphocytes ((7.65 ± 1.64) ％) and OX40L in CD19+ B lymphocytes ((11.50 ±2.72)％) were increased after 131I therapy(t =2.795,2.393,both P ＜0.05).The thyroid functions of 32 GD patients were improved.The levels of FT3,FT4 and TRAb decreased significantly after 131I treatment (from 20.79 ±6.05 to 4.53 ± 2.54,from 49.65 ± 10.12 to 13.69 ± 4.35,and from 24.78 ± 8.46 to 11.74 ±6.19,respectively; t =2.219,2.441 and 2.293,all P＜0.05).The levels of FT3 and FT4 were positively correlated with the percentage of OX40 expression in CD4+ T lymphocytes (r =0.65 and 0.73,both P ＜ 0.05).TRAb was positively correlated with CD19+ OX40L + B lymphocytes (r =0.76,P ＜ 0.05).Conclusions OX40/OX40L may play an important role in the activation of lymphocytes,the production of antibodies,and participate in the pathogenesis and progression of GD.131I therapy not only damages most of the thyroid follicular epithelial cells by its β ray,but also facilitates GD improvement by regulating T and B lymphocyte functions.
